MedPath

The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic"

Terminated
Conditions
COVID-19
Cancer
Registration Number
NCT04581070
Lead Sponsor
Cancer Trials Ireland
Brief Summary

This is a prospective, multisite, descriptive, observational clinical/epidemiological study examining both quantitative and qualitative data pertaining to clinical outcomes and organizational responses to the 2020 SARS-Coronavirus-2 (SARS-CoV-2) pandemic.

Detailed Description

This study collects real-time observational data regarding the impact of SARS-CoV-2 infection on patients with cancer, and on the functioning and organisation of cancer and malignant haematology services in the Republic of Ireland in response to the 2020 SARS-CoV-2 pandemic.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
4
Inclusion Criteria
  1. Age ≥ 18
  2. Informed consent has been obtained.
  3. Cytotoxic chemotherapy, targeted anticancer therapy, immunomodulatory anticancer therapy, hormonotherapy, radiotherapy, oncologic surgery, or other anticancer treatment within the last 12 months (ongoing and completed).
  4. Tested positive for SARS-CoV-2.
Exclusion Criteria

There are no exclusion criteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
A qualitative descriptionUp til 1 year

A qualitative narrative description of national cancer care practises and risk mitigation strategies adopted in response to the SARS-CoV-2 pandemic.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Mater Misericordiae University Hospital

🇮🇪

Dublin, Ireland

University Hospital Limerick

🇮🇪

Limerick, Ireland

University Hospital Waterford

🇮🇪

Waterford, Ireland

© Copyright 2025. All Rights Reserved by MedPath